{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T17:22:34Z","timestamp":1791566554428,"version":"4.3.4"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"16","license":[{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"China Capital Characteristic Clinic Project","award":["Z211100002921037"],"award-info":[{"award-number":["Z211100002921037"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4,17]]},"abstract":"<jats:p>Allogeneic hematopoietic cell transplantation (allo-HSCT) is an essential therapeutic modality hematological malignancies, but acute graft-versus-host disease (aGvHD) persists as a leading cause of non-relapse mortality (NRM) . Cytokine biomarkers have already been used to predict aGvHD and outcomes. However, the standard guidelines for aGvHD biomarker panels remain controversial.<\/jats:p>\n                  <jats:p>\n                    We retrospectively analyzed the association of a biomarker panel (suppressor of tumorigenesis 2 [ST2], regenerating islet-derived 3 \u03b1 [REG3\u03b1], Elafin, and tumor necrosis factor 1 [TNFR1]) in serum with the onset of 100-day aGvHD, 12-month NRM, and overall survival (OS) in 141 hematological malignancies patients at 19\u2005\u00b1\u20055 days after allo-HSCT from January 2022 to August 2023. Multivariable analysis showed that ST2 (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.001) were strongly correlated with aGvHD, and TNFR1 was significantly associated with 12-month NRM and OS (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.001). The panel of ST2, REG3\u03b1, Elafin, and TNFR1 demonstrated the best performance in diagnosis of 100-day aGvHD (area under the curve [AUC]\u2005=\u20050.79) and in the prediction of 12-month NRM (AUC\u2005=\u20050.74) and OS (AUC\u2005=\u20050.71). The 4-biomarker panel\u2019s risk classification predicted the 12-month cumulative incidence of NRM (43% vs 11%,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.001) and 12-month OS (51% vs 82%,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.001) for the high-risk and low-risk groups, respectively. Our results suggest that a combination of ST2, REG3\u03b1, Elafin, and TNFR1 is an excellent biomarker predictive panel for aGvHD diagnosis and outcomes after allo-HSCT.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000046150","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T14:01:22Z","timestamp":1776434482000},"page":"e46150","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["A panel of ST2, Reg3\u03b1, Elafin, and TNFR1: Predictive value for acute GvHD and outcomes in hematological malignancy patients post allo-HSCT"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-2308-7472","authenticated-orcid":false,"given":"Qi","family":"Hao","sequence":"first","affiliation":[{"name":"Department of Hematology, Aerospace Center Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyue","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Aerospace Center Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, Aerospace Center Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Hematology, Aerospace Center Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianqi","family":"Qi","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Aerospace Center Hospital, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuqin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Aerospace Center Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinhong","family":"Fei","sequence":"additional","affiliation":[{"name":"Department of Hematology, Aerospace Center Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangying","family":"Gu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Aerospace Center Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9190-0922","authenticated-orcid":false,"given":"Jingbo","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Aerospace Center Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260605","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMra1609337","article-title":"Acute graft-versus-host disease - biologic process, prevention, and therapy.","volume":"377","author":"Zeiser","year":"2017","journal-title":"N Engl J Med"},{"key":"R2-20260605","first-page":"1","article-title":"Acute graft-versus-host disease: a brief review.","volume":"37","author":"Aladag","year":"2020","journal-title":"Turk J Haematol"},{"key":"R3-20260605","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s00277-024-05952-0","article-title":"Recent advances in acute gastrointestinal graft versus host disease (aGvHD): aspects of steroid-resistant disease.","volume":"104","author":"Kujawska","journal-title":"Ann Hematol"},{"key":"R4-20260605","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","article-title":"International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai acute GVHD international consortium.","volume":"22","author":"Harris","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"R5-20260605","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/S2352-3026(14)00035-0","article-title":"A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study.","volume":"2","author":"Levine","year":"2015","journal-title":"Lancet Haematol"},{"key":"R6-20260605","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/bmt.2010.165","article-title":"Biomarkers of immune activation to screen for severe, acute GVHD.","volume":"46","author":"August","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"R7-20260605","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1182\/blood-2008-02-138867","article-title":"Change in plasma tumor necrosis factor receptor 1 levels in the first week after myeloablative allogeneic transplantation correlates with severity and incidence of GVHD and survival.","volume":"112","author":"Choi","year":"2008","journal-title":"Blood"},{"key":"R8-20260605","doi-asserted-by":"crossref","first-page":"4604","DOI":"10.4049\/jimmunol.1500117","article-title":"Cytokines in graft-versus-host disease.","volume":"194","author":"Henden","year":"2015","journal-title":"J Immunol"},{"key":"R9-20260605","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/j.bbmt.2016.04.022","article-title":"The role of biomarkers in the diagnosis and risk stratification of acute graft-versus-host disease: a systematic review.","volume":"22","author":"Ali","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"R10-20260605","doi-asserted-by":"crossref","first-page":"6702","DOI":"10.1182\/blood-2011-08-375006","article-title":"Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease.","volume":"118","author":"Ferrara","year":"2011","journal-title":"Blood"},{"key":"R11-20260605","doi-asserted-by":"crossref","first-page":"13ra2","DOI":"10.1126\/scitranslmed.3000406","article-title":"Elafin is a biomarker of graft-versus-host disease of the skin.","volume":"2","author":"Paczesny","year":"2010","journal-title":"Sci Transl Med"},{"key":"R12-20260605","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1182\/blood-2014-06-584789","article-title":"High day 28 ST2 levels predict for acute graft-versus-host disease and transplant-related mortality after cord blood transplantation - ScienceDirect.","volume":"125","author":"Ponce","year":"2015","journal-title":"Blood"},{"key":"R13-20260605","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1182\/blood-2014-10-606830","article-title":"The IL-33\/ST2 axis augments effector T-cell responses during acute GVHD.","volume":"125","author":"Reichenbach","year":"2015","journal-title":"Blood"},{"key":"R14-20260605","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1182\/bloodadvances.2022008480","article-title":"Reg3\u03b1 concentrations at day of allogeneic stem cell transplantation predict outcome and correlate with early antibiotic use.","volume":"7","author":"Weber","year":"2023","journal-title":"Blood Adv"},{"key":"R15-20260605","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s00277-021-04727-1","article-title":"Elevated REG3\u03b1 predicts refractory aGVHD in patients who received steroids-ruxolitinib as first-line therapy.","volume":"101","author":"Yang","year":"2022","journal-title":"Ann Hematol"},{"key":"R16-20260605","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1016\/j.bbmt.2019.12.123","article-title":"The MAGIC algorithm probability (MAP) is a validated response biomarker of treatment for acute graft-versus-host disease.","volume":"26","author":"Srinagesh","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"R17-20260605","doi-asserted-by":"crossref","first-page":"e124015","DOI":"10.1172\/jci.insight.124015","article-title":"An early-biomarker algorithm predicts lethal graft-versus-host disease and survival.","volume":"3","author":"Hartwell","year":"2018","journal-title":"JCI Insight"},{"key":"R18-20260605","doi-asserted-by":"crossref","first-page":"e130413","DOI":"10.1172\/jci.insight.130413","article-title":"A panel of 4 biomarkers for the early diagnosis and therapeutic efficacy of aGVHD.","volume":"4","author":"Li","year":"2019","journal-title":"JCI Insight"},{"key":"R19-20260605","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00277-023-05502-0","article-title":"CLAG combined with total body irradiation as intensive conditioning chemotherapy prior to allogeneic hematopoietic stem cell transplantation in patients with refractory or relapsed acute myeloid leukemia.","volume":"103","author":"Fei","year":"2024","journal-title":"Ann Hematol"},{"key":"R20-20260605","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1182\/bloodadvances.2023011049","article-title":"Amphiregulin, ST2, and REG3\u03b1 biomarker risk algorithms as predictors of nonrelapse mortality in patients with acute GVHD.","volume":"8","author":"Etra","year":"2024","journal-title":"Blood Adv"},{"key":"R21-20260605","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/bjh.18300","article-title":"A biomarker signature to predict complete response to itacitinib and corticosteroids in acute graft-versus-host disease.","volume":"198","author":"Pratta","year":"2022","journal-title":"Br J Haematol"},{"key":"R22-20260605","doi-asserted-by":"crossref","first-page":"355","DOI":"10.3906\/sag-2007-17","article-title":"Assessment of ST2 and Reg3a levels in patients with acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.","volume":"51","author":"Alada\u011e","year":"2021","journal-title":"Turk J Med Sci"},{"key":"R23-20260605","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1056\/NEJMoa1213299","article-title":"ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death.","volume":"369","author":"Vander Lugt","year":"2013","journal-title":"N Engl J Med"},{"key":"R24-20260605","doi-asserted-by":"crossref","first-page":"2293497","DOI":"10.1080\/16078454.2023.2293497","article-title":"Diagnostic and prognostic role of Elafin in skin acute graft versus host disease: a systematic review.","volume":"29","author":"Bhattarai","year":"2024","journal-title":"Hematology"},{"key":"R25-20260605","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1182\/blood-2011-10-387357","article-title":"Plasma biomarkers of lower gastrointestinal and liver acute GVHD.","volume":"119","author":"Harris","year":"2012","journal-title":"Blood"},{"key":"R26-20260605","doi-asserted-by":"crossref","first-page":"988.e1","DOI":"10.1016\/j.jtct.2021.08.021","article-title":"Evaluation of Elafin as a prognostic biomarker in acute graft-versus-host disease.","volume":"27","author":"Zewde","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"R27-20260605","first-page":"13","article-title":"Elafin is a biomarker of graft-versus-host disease of the skin.","volume":"15","author":"Paczesny","year":"2009","journal-title":"Sci Transl Med"},{"key":"R28-20260605","doi-asserted-by":"crossref","first-page":"3707","DOI":"10.1182\/bloodadvances.2022007296","article-title":"Assessment of systemic and gastrointestinal tissue damage biomarkers for GVHD risk stratification.","volume":"6","author":"Etra","year":"2022","journal-title":"Blood Adv"},{"key":"R29-20260605","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/S2352-3026(23)00342-3","article-title":"Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation.","volume":"11","author":"Penack","year":"2024","journal-title":"Lancet Haematol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000046150","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T16:00:32Z","timestamp":1780675232000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000046150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":29,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000046150","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,17]]},"assertion":[{"value":"2025-07-22","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-15","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}